<table id="ID70" width="99%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Rifabutin Interaction Studies</caption>
<col width="16%"></col>
<col width="16%"></col>
<col width="10%"></col>
<col width="10%"></col>
<col width="10%"></col>
<col width="15%"></col>
<col width="22%"></col>
<tfoot>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">↑ indicates increase; ↓ indicates decrease; ↔ indicates no significant change <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">QD-once daily; BID-twice daily; TID – thrice daily <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">ND -No Data <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">AUC -Area under the Concentration vs. Time Curve; C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> -Maximum serum concentration <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>a</sup>
<sup></sup>compared to rifabutin 300 mg QD alone <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>b</sup>
<sup></sup>compared to historical control (fosamprenavir/ritonavir 700/100 mg BID) <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>c</sup>
<sup></sup>also taking zidovudine 500 mg QD<br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>d</sup>
<sup></sup>compared to rifabutin 150 mg QD alone <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>e</sup>
<sup></sup>compared to rifabutin 300 mg QD alone <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>f</sup>
<sup></sup>data from a case report <br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="7">
<paragraph stylecode="Footnote">
<sup>g</sup>
<sup></sup>compared to voriconazole 200 mg BID alone <br/>
</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Coadministered </content>
<content stylecode="bold">drug </content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Dosing </content>
<content stylecode="bold">regimen </content>
<content stylecode="bold">of </content>
<content stylecode="bold">coadministered </content>
<content stylecode="bold">drug</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Dosing </content>
<content stylecode="bold">regimen </content>
<content stylecode="bold">of </content>
<content stylecode="bold">rifabutin</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Study </content>
<content stylecode="bold">population </content>
<content stylecode="bold">(</content>
<content stylecode="bold">n</content>
<content stylecode="bold">)</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Effect </content>
<content stylecode="bold">on </content>
<content stylecode="bold">rifabutin</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Effect </content>
<content stylecode="bold">on </content>
<content stylecode="bold">coadministered </content>
<content stylecode="bold">drug</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Recommendation</content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ANTIVIRALS </content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Amprenavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">1200 mg BID x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy male subjects (6)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 193%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 119%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 50%. Monitor closely for adverse reactions.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Delavirdine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">400 mg TID<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (7)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 230%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 128%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 80%, ↓ Cmax by 75%,<br/>↓ C<sub>m</sub>
<sub>i</sub>
<sub>n</sub> by 17%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">CONTRAINDICATED</content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Didanosine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">167 or 250 mg BID x 12 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 or 600 mg QD x 1<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (11)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Fosamprenavir/ ritonavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">700 mg BID plus ritonavir 100 mg BID x 2 weeks<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg every other day x 2 weeks<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (15)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔ AUC<sup>a</sup>
<sup> </sup>↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 15%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 35%<sup>b</sup>,<br/>↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 36%, ↑ C<sub>m</sub>
<sub>i</sub>
<sub>n</sub> by 36%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with fosamprenavir/ritonavir combination.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Indinavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">800 mg TID x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (10)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 173%, ↑ Cmax by 134%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 34%, ↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 25%, ↓ C<sub>m</sub>
<sub>i</sub>
<sub>n</sub> by 39%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by 50%, and increase indinavir dose from 800 mg to 1000 mg TID.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Lopinavir/<br/>ritonavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">400/100 mg BID x 20 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg QD x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (14)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 203%<sup>c</sup>
<br/>↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub>
<sub> </sub>by 112%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Saquinavir/ ritonavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">1000/100 mg BID x 14 or 22 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg every 3 days X 21 to 22 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 53% <sup>d</sup> ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 88% (n=11)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 13%, ↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 15%, (n=19)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with saquinavir/ritonavir combination. Monitor closely for adverse reactions.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Ritonavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">500 mg BID x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg QD x 16 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (5)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 300%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 150%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Tipranavir/ ritonavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">500/200 BID X 15 doses<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg single dose<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (20)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 190%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 70%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with tipranavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Nelfinavir <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">1250 mg BID x 7 to 8 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">150 mg QD x 8 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (11)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 83%,<sup>e</sup> ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 19%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reduce rifabutin dose by 50% (to 150 mg QD) and increase the nelfinavir dose to 1250 mg BID<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Zidovudine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">100 or 200 mg q4h<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 or 450 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (16)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 32%, ↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 48%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Because zidovudine levels remained within the therapeutic range during coadministration of rifabutin, dosage adjustments are not necessary.<br/>
</td>
</tr>
<tr>
<td align="left" colspan="4" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ANTIFUNGALS </content>
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Fluconazole <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">200 mg QD x 2 weeks<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD x 2 weeks<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (12)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 82%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 88%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor for rifabutin associated adverse events. Reduce rifabutin dose or suspend rifabutin use if toxicity is suspected.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Posaconazole <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">200 mg QD x 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD x 17 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (8)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 72%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 31%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 49%, ↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 43%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of posaconazole efficacy.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Itraconazole <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">200 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-Infected patients (6)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑<sup>f</sup>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 70%, ↓ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 75%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of itraconazole efficacy. In a separate study, one case of uveitis was associated with increased serum rifabutin levels following coadministration of rifabutin (300 mg QD) with itraconazole (600 to 900 mg QD).<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Voriconazole <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">400 mg BID x 7 days (maintenance dose)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD x 7 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy male subjects (12)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 331%, ↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by 195%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by ~100%,<br/>↑ C<sub>m</sub>
<sub>a</sub>
<sub>x</sub> by ~100%<sup>g</sup>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">CONTRAINDICATED</content>
<br/>
</td>
</tr>
<tr>
<td align="left" colspan="4" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ANTI</content>
<content stylecode="bold">-</content>
<content stylecode="bold">PCP </content>
<content stylecode="bold">(</content>
<content stylecode="bold">Pneumocystis </content>
<content stylecode="bold">carinii </content>
<content stylecode="bold">pneumonia</content>
<content stylecode="bold">) </content>
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
<td align="left" colspan="1" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Dapsone <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">50 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (16)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 27 to 40%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Sulfamethoxazole-Trimethoprim <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">800/160 mg<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (12)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 15 to 20%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" colspan="7" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ANTI</content>
<content stylecode="bold">-</content>
<content stylecode="bold">MAC </content>
<content stylecode="bold">(</content>
<content stylecode="bold">Mycobacterium </content>
<content stylecode="bold">avium </content>
<content stylecode="bold">intracellulare </content>
<content stylecode="bold">complex</content>
<content stylecode="bold">) </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Azithromycin <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">500 mg QD x 1 day, then 250 mg QD x 9 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (6)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Clarithromycin <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">500 mg BID<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (12)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ AUC by 75%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ AUC by 50%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor for rifabutin associated adverse events. Reduce dose or suspend use of rifabutin if toxicity is suspected. Alternative treatment for clarithromycin should be considered when treating patients receiving rifabutin<br/>
</td>
</tr>
<tr>
<td align="left" colspan="7" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ANTI</content>
<content stylecode="bold">-</content>
<content stylecode="bold">TB </content>
<content stylecode="bold">(</content>
<content stylecode="bold">Tuberculosis</content>
<content stylecode="bold">) </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Ethambutol <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">1200 mg<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD X 7 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (10)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Isoniazid <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD X 7 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (6)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" colspan="7" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">OTHER </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Methadone <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">20 to 100 mg QD<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD X 13 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">HIV-infected patients (24)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Ethinylestradiol (EE)/ Norethindrone (NE) <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">35 mg EE / 1 mg NE X 21 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg QD X 10 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy female subjects (22)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">EE: ↓ AUC by 35%,<br/>↓ Cmax by 20% NE: ↓ AUC by 46%<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Patients should be advised to use additional or alternative methods of contraception.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Theophylline <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">5 mg/kg<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">300 mg X 14 days<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Healthy subjects (11)<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">ND<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↔<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
</tbody>
</table>